Roche reviews Germany investments over healthcare cost cuts; Gilead bowel drug advances

Roche is reviewing all future investments in Germany, citing loss of trust over healthcare cost-cutting policies, signaling potential capital reallocation. Separately, Gilead's bowel disease drug shows progress. The investment review could affect Germany's biotech sector and Roche's European footprint, though no concrete decisions have been announced.